This event has run. Thank you to our speakers, sponsors, and delegates who joined us for the 2026 summit.

Radiopharm Doses First Patient in Phase I Prostate Cancer Radiotherapy Study
Alpha‑Emitting PSMA Therapies Gain Momentum Across Radiopharma Leaders
Ratio Therapeutics Highlights the Next Wave of Radiopharmaceutical Manufacturing Standards
Radiopharma Veterans From Novartis‑Built Platforms Strengthen Emerging Biotechs
Radiopharma Takes Center Stage as Global Biopharma Partnering Accelerates

Beyond Systemic RLT: Phase 2 Evidence of Local Alpha Therapy to Prevent Peritoneal Recurrence

Beyond Systemic RLT: Phase 2 Evidence of Local Alpha Therapy to Prevent Peritoneal Recurrence

5:00 pm - Wednesday 22nd July 2026

Limitations of systemic radioligand therapies in addressing microscopic peritoneal disease
Scientific and clinical rationale for intraperitoneal delivery of alpha-emitting radiopharmaceuticals
Development strategy for Radspherin® targeting prevention of peritoneal recurrence following surgery

Speakers:

Ramzi Amri

Chief Financial Officer

Oncoinvent AS